REGN7508 + Apixaban for Blood Clots in Cancer Patients

(ROXI-CAT-II Trial)

This trial tests a new drug, REGN7508, to determine its safety and effectiveness in treating blood clots in individuals with or without cancer. Blood clots can obstruct blood flow in veins (deep vein thrombosis, or DVT) or lungs (pulmonary embolism, or PE). The trial compares REGN7508 to the commonly used blood thinner, apixaban, to evaluate which is more effective. It suits individuals recently diagnosed with blood clots in the legs or lungs who require long-term blood-thinning treatment. The study will also assess side effects and how the body processes the drug. As a Phase 3 trial, it represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should be on a therapeutic dose of a Direct Oral Anticoagulant (DOAC) for at least 3 to 6 months, depending on the part of the study. It's best to discuss your current medications with the study team.

Research has shown that REGN7508 has undergone safety testing in several studies. It aims to prevent blood clots, particularly in cancer patients. Some studies indicate that REGN7508 can reduce the risk of blood clots without increasing bleeding, a significant advantage since many blood clot treatments can cause bleeding.

Although regulatory authorities have not yet fully evaluated the safety and effectiveness of REGN7508, studies so far suggest it is generally well-tolerated. These studies have reported no major severe side effects. However, like any new treatment, it continues to undergo study to confirm these results.

In contrast, apixaban is already approved for preventing and treating blood clots and is known to be effective and generally safe. Participants in this trial will receive either REGN7508 or apixaban, making it important to understand the safety of both treatments.

Most treatments for blood clots in cancer patients, such as blood thinners like warfarin or low molecular weight heparin, work by preventing new clots from forming, but they come with a risk of bleeding. Researchers are excited about REGN7508 because it may offer a new approach by specifically targeting pathways involved in cancer-related clotting, potentially reducing the risk of bleeding compared to current options. Meanwhile, Apixaban is already a known player in the game, but its combination with REGN7508 could enhance its efficacy and safety, making this duo a promising candidate for better management of blood clots in cancer patients.

Research has shown that REGN7508, which participants in this trial may receive, helps prevent blood clots. In one study, only 7% of patients who took the drug developed blood clots, compared to 21% who did not take it. This finding indicates that the drug has a strong protective effect against clots. Another study found that REGN7508 reduced clotting events without causing major bleeding. These results suggest that REGN7508 could be a promising option for people with cancer who are at risk of blood clots. Meanwhile, researchers are also studying Apixaban, another treatment option in this trial, for its effectiveness in preventing blood clots in cancer patients.¹⁶⁷⁸⁹